Background Patients who have been on continuous ambulatory peritoneal dialysis (CAPD) for over 10 years are known to have a risk of developing encapsulating peritoneal sclerosis (EPS). However, the prognosis of patients on CAPD for over 10 years remains unclear. Methods To better understand the efficacy of a variety of treatments for EPS, we retrospectively reviewed 25 patients who started CAPD at Toranomon Hospital from 1981 to 1997 and continued it for longer than 10 years. Results The CAPD catheter was removed without peritoneal lavage in the initial 3 patients and they developed massive ascites. They all died of infection without resolution of the ascites. Accordingly, in the remaining 13 patients who did not undergo kidney transplantation, peritoneal lavage therapy was performed for 12 months before removing the CAPD catheter. As a result, 4 patients did not develop EPS. However, 9 patients had EPS with ascites, among whom 4 died of EPS-related diseases and 5 are alive. Five patients underwent cadaveric donor kidney transplantation. At the time of surgery, the CAPD catheter was removed without peritoneal lavage; 1 patient suffered from massive ascites immediately, although this subsided within 3 months after kidney transplantation, and 4 patients remain free from EPS-related symptoms and are doing well. Conclusion Kidney transplantation may be an option for preventing EPS. This study showed that improvement of the uremic state as well as treatment with immunosuppressants including corticosteroids may contribute to preventing EPS.
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Prognosis of Patients on Continuous Ambulatory Peritoneal Dialysis (CAPD) for Over 10 Years
Introduction
As early as 1980, encapsulating peritonitis sclerosis (EPS) was reported as a possible complication of continuous ambulatory peritoneal dialysis (CAPD) (1) . Now EPS is known to be a fatal complication in patients who have been on CAPD for longer than 10 years in Japan where donor kidneys for transplantaion are in very short supply. Since 68.6% of EPS is reported to occur after stopping CAPD, 2 stages have been postulated in the development of EPS (2) . In the first stage, massive ascites begins to ooze from the sclerosing peritoneum after removal of the CAPD catheter. This is known as the pre-EPS state. Thereafter, the intestine becomes enclosed in a sac of fibrous tissue, resulting in ileus associated with bowel obstruction. This is known as definite EPS. It is important to detect the pre-EPS state as soon as possible, and administration of immunosuppressants including corticosteroids is recommended to treat this condition (3). For definite EPS, a variety of treatments have been tried, including corticosteroids (4-6), peritoneal rest (2), and surgical enterolysis (2, 7). To prevent pre-EPS, peritoneal lavage therapy before the removal of CAPD has been proposed as a potentially effective option (8) (9) (10) . Kidney transplantation has also been reported as effective, possibly due to the influence of the immunosuppressive therapy given to transplant patients (11) . To better understand the efficacy of these therapies, we retrospectively reviewed 25 patients who had been on CAPD for longer than 10 years.
Materials and Methods
Patients
Twenty-five patients who started CAPD at Toranomon hospital from 1981 to 1997 and continued it for longer than 10 years were reviewed retrospectively in April 2010. CAPD is usually switched to hemodialysis after less than 10 years because of failure of peritoneal ultrafiltration or fatal peritonitis. However, these patients had been doing well without such episodes and had hoped to continue with CAPD. Their mean age was 44.2±14.7 years (range: 1 to 78 years) at the start of CAPD, and the average duration of CAPD was 12.2±1.8 years (10 to 17 years). The number of peritonitis episodes was 1.17±1.83 (0-5) per patient. The peritoneal equilibration test (PET) at the cessation of CAPD showed a high average result in 20 patients and was high in 5 patients, but cytology, or CA125 and MMP3 levels in the CAPD dialysate were not evaluated. Their residual renal function during the last 1 to 3 years before cessation of CAPD was minimal with less than 50 ml of urine daily.
The average observation period for the survivors in 2010 was 6.0±4.2 years (2 to 14 years). The main cause of endstage renal disease was glomerulonephritis (Table 1 , 2). The female to male ratio was 12:13.
Diagnosis
Definite EPS was diagnosed from symptoms such as nausea, vomiting, and abdominal pain, and radiological findings such as dilated small bowel loops, thickening of the bowel wall, and air-fluid levels indicating bowel obstruction (ileus). Patients with ascites confirmed by CT or ultrasound were also classified as having preEPS.
Results
Prognosis
The mortality and morbidity of the 25 patients was evaluated in relation to the occurrence of EPS (Table 2 ). EPS ("yes" in Table 2 ) shows the peritoneal histology of EPS as well as the clinical features of EPS.
Four of the 25 patients died of heart failure, MRSA peritonitis, colon cancer, and biliary cancer before the removal of the catheter before stopping CAPD, so the remaining 21 patients were evaluated (Fig. 1) . Of the 16 patients who did not undergo kidney transplantation, the first 3 patients (patients 4, 6, and 8 in Table 2 ) had the CAPD catheter removed without prior peritoneal lavage therapy. All 3 patients developed massive ascites from one to three months after catheter removal. Immunosuppressants such as prednisolone (30 to 40 mg daily in all three patients) and/or cyclosporine (100 mg daily in one patient) were administered. However, cachexia and hypoalbuminemia progressed and these patients died of infection without resolution of the ascites.
In the remaining 13 patients who did not undergo kidney transplantation, peritoneal lavage was done once daily with 1.5 L of 1.5% dextrose over 12 months before the CAPD catheter was removed. Four of these 13 patients remained free of ascites and EPS. Three of them are doing well, but 1 patient died of subarachnoid hemorrhage (SAH) at 2 years after removal of the CAPD catheter. The remaining 9 patients developed ascites and/or EPS (8 patients had ascites and EPS, while 1 patient had EPS without ascites). Four of these 9 patients underwent surgical adhesiolysis. As a result, 1 patient is doing well without ileus, 1 patient still has recurrent mild ileus, 1 patient died of intestinal perforation 4 months after surgery, and 1 patient had recurrent ileus and died of cardiovascular disease. Among the 5 patients who did not have surgery, 3 are doing well despite recurrent mild ileus, but 2 patients died of ileus-related complications. Prednisolone was administered (30 to 40 mg on alternate days) to 5 out of 9 patients. Two of them died and 3 are alive. Among the 4 patients who did not receive prednisolone, 2 died and 2 are alive.
Five patients underwent cadaveric donor kidney transplantation ( Fig. 1, 2) . At the time of surgery, the CAPD catheter was removed without peritoneal lavage. The immunosuppressants administered after renal transplantation were as follows: prednisolone (n=5), cyclosporine (n=5), mycophenolate mofetil (n=2), azathioprine (n=1), mizoribine (n=2), gusperimus hydrochloride (n=1), muromonab-CD3 (n=2), and basiliximab (n=3). Four patients did not develop ascites after removal of the CAPD catheter. However, 1 patient suffered from massive ascites immediately after removal of the catheter, although this subsided within 3 months after kidney transplantation. These 5 patients remain free from EPSrelated symptoms and are doing well at 3 to 12 years after 
Discussion
EPS is recognized as a serious complication of CAPD, since the mortality of patients with EPS was reported to be 43.5% in a questionnaire survey performed in Japan in 1996 (12) . Also in 2004, Kawanishi et al showed that the prevalence and the mortality of EPS increase as the duration of CAPD becomes longer in a Japanese multicenter study. The prevalence and the mortality of EPS were respectively 0.7% and 0% (CAPD duration of 3 to 5 years), 2.1% and 8.3% (5 to 8 years), 5.9% and 28.6% (8 to 10 years), 5.8% and 61.5% (10 to 15 years), 17.2% and 100% (>15 years) (2) . Once EPS develops, the prognosis becomes extremely poor. Their study showed the incidence of EPS at a certain period, but did not show the prognosis of all patients after cessation of CAPD. Therefore, there was a limited ability to assess the precise prognosis after cessation of CAPD.
A variety of treatments have been tried for EPS, including corticosteroids, peritoneal lavage (8, 9), peritoneal rest (2), and surgical enterolysis (2, 7). Some reports have suggested that corticosteroid therapy was effective for patients with EPS due to the prevention of fibroneogenesis (3, 6) . Peritoneal lavage therapy has also been reported to be useful for EPS (8-10). The mechanism is considered to be that lavage eliminates factors causing EPS. Hawley et al reported that the immunosuppressive therapy administered after kidney transplantation might be effective for controlling EPS (11) . Although prednisolone was administered before kidney transplantation, EPS did not subside. However, EPS improved after transplantation, suggesting the effectiveness of more powerful immunosuppressive drugs, such as cyclosporine, azathioprine and prednisolone that are administered after transplantation (11) . There is another study showing that the immunosuppressive drugs given after kidney transplantation might improve EPS (5) . In that study, 4 out of 17 patients with EPS underwent kidney transplantation. In one patient, EPS-related symptoms recurred after immunosuppressive therapy was discontinued because of kidney graft failure and symptoms subsided after restarting immunosuppressive therapy. Cyclosporine, azathioprine and prednisolone were administered to these patients. On the other hand, there are two reports of EPS occurring for the first time after renal transplantation. Dejagere et al reported a case of new-onset EPS after renal transplantation and suggested that rapid tapering of corticosteroids may be responsible for EPS (13) . Fieren et al reported 7 cases of EPS developing after kidney transplantation (14) . They concluded that renal transplantation itself may be implicated in the onset or progression of EPS, and that rapid reduction of corticosteroid doses due to the use of other immunosuppressive agents after transplantation also contributed to the establishment of EPS because corticosteroids play the most important role in the prevention of this condition (15) . However, they did not report the total number of CAPD patients receiving renal transplantation during the same period at their institution, so the rate of EPS after renal transplantation remains unclear.
Patients who have been on CAPD for over 10 years are known to have a risk of developing EPS. The present study shows the long-term prognosis of EPS in patients on chronic CAPD, as well as the effectiveness of various treatments, including corticosteroids, kidney transplantation, and peritoneal lavage after the cessation of CAPD. Recently, Lafrance et al reported a patient in whom EPS was improved dramatically by immunosuppressive therapy using colchicine, prednisone, and mycophenolate mofetil (MMF) (15) . This regimen may become a new option for EPS. A randomized controlled study that compares patients with and without kidney transplantation receiving the same immunosuppressive treatment would be needed to prove the efficacy of transplantation itself.
In conclusion, our study showed that patients receiving kidney transplantation had the best prognosis after the removal of the CAPD catheter. We consider that improvement of the uremic state as well as immunosuppression may contribute to the prevention of EPS. More effective prevention for the development of EPS must be considered in Japan, where there is a very small number of cadaver donors for kidney transplantation.
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